The NINDS Topics in Clinical Research Seminar Series presents, Welcome to the Bright Side: Careers in the Biopharmaceutical Industry.
Please log on for the next Topics in Clinical Research meeting where we welcome Dietrich Haubenberger, MD, MHSc, FAAN, Vice President, Translational Medicine, Neurocrine Biosciences Inc., & Voluntary Associate Clinical Professor, University of California San Diego - Dept. of Neurosciences as he presents on Careers in the Biopharmaceutical Industry.
This talk will:
- Highlight career paths for neurologists in industry;
- Share personal experiences from Dr. Haubenberger’s path from academia - via NINDS - to industry;
- Provide insights and practical advice on successfully transitioning to the biopharmaceutical industry.
…with Q&A to follow!
Dr. Dietrich Haubenberger received his medical and postgraduate training as neurologist at the Medical University of Vienna, Austria, followed by a post-doctoral fellowship at the National Institutes of Health in Bethesda, MD, conducting clinical research projects on genetics, disease mechanisms, outcome measure development, as well as clinical trials involving novel therapies for neurological movement disorders including tremor, dystonia, and Parkinson’s disease. After returning to the Medical University of Vienna in 2011, Dr. Haubenberger lead the Clinical Neurophysiology service at the Dept. of Neurology, received his Habilitation, and was promoted to Associate Professor in Neurology. In 2014, Dr. Haubenberger returned to NIH (NINDS) as Director of the NINDS Clinical Trials Unit and Assistant Clinical Director for Clinical Research, where he oversaw over 100 ongoing neurological clinical research studies at the world’s largest research hospital, the NIH Clinical Center, including emerging modalities such as gene therapy and non-invasive brain stimulation.
In 2019, Dr. Haubenberger transitioned to Neurocrine Biosciences (San Diego, CA), where as Vice President he leads Neurocrine’s Department for Translational Medicine. Dr. Haubenberger had been the clinical lead in early and late-stage drug development programs for neurological diseases with high unmet need for novel therapeutics and is leading translational biomarkers group. Dr. Haubenberger lead the development program for valbenazine in the treatment of Chorea associated with Huntington’s Disease, which resulted in a New Drug Application approval by the U.S. Food and Drug Administration (FDA) in 2023. Further, Dr. Haubenberger holds a Voluntary Associate Clinical Professor position at the Dept. of Neurosciences, University of California San Diego (UCSD) and serves on the Council for Research, Science, Innovation and Technology of the Austrian Federal Government.